+44 (0)20 8817 5296info@tritrials.com

Resources

OPRA Slide Presentations

Why? If a company wants to take a risk-based approach to monitoring, it must be able to prove it has a quality risk management plan which it executed, measured, and adjusted over time. How? TRI developed a purpose built application based on industry guidance that identifies site quality risk and allows central management of monitoring and risk mitigation activities What? OPRA…

Read More

Protocol Risk Assessment Made Simple

(Expired) Protocol Risk Assessment – limited attendance Why is this webinar so important? Protocol Risk Assessment is the genesis of the new Quality Management section (5) of ICH E6 (R2) and core to the principles of quality by design (QBD). It drives much of the downstream quality planning and management activity during the course of a clinical trial and…

Read More

TransCelerate RBM Volume II 15JUL2014

TransCelerate’s Risk-Based Monitoring (RBM) project has been productive in the first half of 2014. The purpose of RBM Update Volume II is to share new and relevant information on the accomplishments of the RBM workstream including the following: RACT version 2.0 released on April 29, 2014 Central Monitoring Capability Technology Considerations to Enable RBM External Engagement Upcoming Deliverables in…

Read More

TransCelerate RBM Volume I 27JAN2014

TransCelerate’s Risk-Based Monitoring (RBM) project had a very productive year in 2013. Subsequent to publishing the Position Paper on Risk-Based Monitoring Methodology in May 2013, we have actively worked to network the concepts and embarked on piloting and/or assessing experience among companies that implemented the methodology. The purpose of this RBM Update document is to share the following information…

Read More

TransCelerate RBM Position Paper 30May2013

Current On-site Monitoring practices are frequency-based, conform to a prescribed monitoring visit schedule, and provide generalized quality control at investigational sites. Although this practice does provide a level of control, advances in risk-based approaches and technology provide an opportunity for a more holistic and proactive approach through Off-site and Central Monitoring and a targeted approach to On-site Monitoring. By…

Read More

FDA Guidance on RBM (2013)

This guidance assists sponsors of clinical investigations in developing risk-based monitoring strategies and plans for investigational studies of medical products, including human drug and biological products, medical devices, and combinations thereof. The overarching goal of this guidance is to enhance human subject protection and the quality of clinical trial data by focusing sponsor oversight on the most important aspects…

Read More

EMA Reflection Paper on RBM (2013)

Good clinical practice (GCP)1 is a set of internationally recognised ethical and scientific standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. ICH GCP requires in Section 5.1, that the sponsor implements and maintains systems for quality assurance and quality control; similarly the Article 2 of the GCP Directive 2005/28/EC requires the implementation…

Read More

Large Pharma RBM Implementation

Our client had strong ambitions to implement both risk-based monitoring (RBM) systems and processes across the entire global organization by the end of 2015. They had chosen a system to adapt to their needs and planned to work to the TransCelerate key risk indicators (KRIs). They needed support in developing the technology to meet their needs, needed guidance on…

Read More

ICD E6 (R2) EMA Adopted Guidelines (Jan 2017)

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that…

Read More

TRI to sponsor 8th annual Clinical Quality Oversight Forum

8th Annual Clinical Quality Oversight Forum With the adoption of ICH E6 (R2) by the EMA this month, and planned adoption for the FDA later this year, this event has never been more important or relevant to the way in which we conduct and oversee clinical trials. TRI’s CEO Duncan Hall will be presenting alongside Advanced Clinical’s SVP of…

Read More

Advanced Clinical and TRI to deliver RBM Round Table Event in San Francisco

Tuesday, May 9, 2017,    8:00am-11:00am,    Burlingame, Embassy Suites San Francisco, Airport-Waterfront   The implementation and operationalization of Risk-based monitoring is a challenge for any company. With ICH E6 (R2) being formally implemented this year, RBM is becoming an increasingly hot topic, and at the top of the strategic agenda of many sponsor organisations. Advanced Clinical implemented RBM using TRI’s…

Read More

TRI to present at MCC’s Central Monitoring Working Group

TRI are part of the MCC’s solution provider program and are delighted to be working with the MCC in their central monitoring working group. During the presentation, Duncan will cover the following areas:   How KRIs and statistical models can be used in conjunction to provide the insight needed for informed decision making How data analytics can be used…

Read More

Free Webinar – 7th Feb 2017 – Using technology to support ICH E6 (R2) compliance

The video below shows TRI’s CIO Chad Finch introducing the webinar: This webinar is free to attend for anyone who is directly involved in the planning and execution of clinical trials.   WHO SHOULD ATTEND? Anyone who is already running clinical trials using the principles of quality management  as defined by ICH E6 (R2) and risk-based monitoring,  or anyone…

Read More

EMA Announce Adoption Date for ICH E6 (R2)

As seen with ICH E6 (R1), the EMA have led the way, becoming the first to adopt. For convenience, we have added the adopted guidance document to our resources page: ICH E6 (R2) EMA Adopted Guidelines So, after a long year of discussion and delays in 2016, 2017 is going to be the year we really start to see…

Read More